Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

• Published in: Nature biomedical engineering Vol. 3; no. 4; pp. 306 - 317
• Main Authors: Yao, Han, Lan, Jiang, Li, Chushu, Shi, Hubing, Brosseau, Jean-Philippe, Wang, Huanbin, Lu, Haojie, Fang, Caiyun, Zhang, Yao, Liang, Lunxi, Zhou, Xiaolin, Wang, Chaojun, Xue, Yu, Cui, Yun, Xu, Jie
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.04.2019; Nature Publishing Group
• Subjects: 45/70; 45/77; 45/91; 631/154/555; 631/250/251/1574; 631/67/580; 64/60; 692/4017; 692/4028/67/1059; 82/1; 82/29; 96/106; 96/31; 96/35; 96/95; Acyltransferase; Acyltransferases - metabolism; Animals; Antibodies; Apoptosis; B7-H1 Antigen - metabolism; Biomedical and Life Sciences; Biomedical Engineering/Biotechnology; Biomedicine; Cancer; Cell death; Cell Line, Tumor; Cell membranes; Cell surface; Degradation; Domains; Humans; Immune checkpoint; Immune response; Immune response (cell-mediated); Immunity; Immunosurveillance; Intracellular; Ligands; Lipids; Lipoylation; Lymphocytes T; Lysosomes; Lysosomes - metabolism; Mice; Neoplasms - immunology; Palmitoylation; Palmitoyltransferase; PD-1 protein; PD-L1 protein; Peptides - metabolism; T-Lymphocytes - immunology; Tumors; Ubiquitination

Checkpoint blockade therapy targeting the programmed-death ligand 1 (PD-L1) and its receptor programmed cell death 1 promotes T-cell-mediated immunosurveillance against tumours, and has been associated with marked clinical benefit in cancer patients. Antibodies against PD-L1 function by blocking PD-...